Pharma Surge
Pharma Surge
Intelligence Layer
๐Ÿ‡บ๐Ÿ‡ธยท19h agoResearch

NCT07388550: Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)

Study type: INTERVENTIONAL. Phase: PHASE1.

Publisher

C
ClinicalTrials.gov

USA

This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.

Read original

At a glance

Publisher
ClinicalTrials.gov
Region
USA
Scope
Research
Published
June 24, 2026
Language
EN

In-platform summary, original article off-platform

This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.

Summary excerpt

Study type: INTERVENTIONAL. Phase: PHASE1.

Source route

Continue on clinicaltrials.gov

Leave the platform to read the original full article on the publisher site.

Source: ClinicalTrials.gov

Scope: Research

Open original article
NCT07388550: Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I) | Pharma Surge